The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Is single-cell sequencing ready for clinical application in AML?
In this video, Koichi Takahashi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the potential of applying single-cell DNA sequencing in the clinic for acute myeloid leukemia (AML). Dr Takahashi believes that combining single-cell DNA sequencing with protein analysis could replace current separate assays, bringing single-cell multi-omics platforms closer to clinical application. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so that’s a million-dollar question that I get every year. But I think we’re getting very close to that point where single cell analysis may be entering the clinic soon. You know, for example, flow cytometry is also a single-cell platform. It’s, you know, analyzing the protein expression of each single cell and reporting these results in clinically actionable results...
Yeah, so that’s a million-dollar question that I get every year. But I think we’re getting very close to that point where single cell analysis may be entering the clinic soon. You know, for example, flow cytometry is also a single-cell platform. It’s, you know, analyzing the protein expression of each single cell and reporting these results in clinically actionable results. I think now that single-cell DNA sequencing also can be combined with the protein analysis, essentially performing simultaneous single-cell DNA analysis as well as protein analysis, could potentially replace the current assays which we separately perform the DNA analysis and the protein analysis. So I think it is really getting close that the single-cell multi-omics platform can be applied to the clinic.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
